AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback
The FDA has indicated that the antibody-drug conjugate looks more promising in a subgroup of EGFR mutated lung cancer patients and AstraZeneca has refiled accordingly.
The FDA has indicated that the antibody-drug conjugate looks more promising in a subgroup of EGFR mutated lung cancer patients and AstraZeneca has refiled accordingly.